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SUMMARY
There is increasing evidence that the lysosome is involved in the pathogenesis of a variety of 
neurodegenerative disorders. Thus, mechanisms that link lysosome dysfunction to the disruption 
of neuronal homeostasis offer opportunities to understand the molecular underpinnings of 
neurodegeneration and potentially identify specific therapeutic targets. Here, using a monogenic 
neurodegenerative disorder, NPC1 disease, we demonstrate that reduced cholesterol efflux from 
lysosomes aberrantly modifies neuronal firing patterns. The molecular mechanism linking 
alterations in lysosomal cholesterol egress to intrinsic tuning of neuronal excitability is a 
transcriptionally mediated upregulation of the ABCA1 transporter, whose PtdIns(4,5)P2-floppase 
activity decreases plasma membrane PtdIns(4,5)P2. The consequence of reduced PtdIns(4,5)P2 is a 
parallel decrease in a key regulator of neuronal excitability, the voltage-gated KCNQ2/3 potassium 
channel, which leads to hyperexcitability in NPC1 disease neurons. Thus, cholesterol efflux from 
lysosomes regulates PtdIns(4,5)P2 to shape the electrical and functional identity of the plasma 
membrane of neurons in health and disease.
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NPC1 disease is a neurodegenerative disorder that occurs due to mutations in the lysosomal NPC1 
cholesterol transporter. Vivas et al. define steps in the pathogenic cascade, downstream of 
lysosomal cholesterol accumulation, that lead to hyperexcitability in NPC1 disease neurons.
Graphical Abstract
INTRODUCTION
Neurodegeneration is a common feature of many neurological disorders. Cell biological, 
genetic, and in vivo work increasingly emphasizes the crucial role that lysosomes play in 
neurodegeneration. Once simply thought of as acidic centers for degradation and recycling, 
lysosomes are now known to be highly dynamic signaling organelles that can mediate signal 
transduction via the mammalian target of rapamycin complex 1 (mTORC1) and regulate 
gene expression via transcription factor EB (TFEB) and other transcription factors (Laplante 
and Sabatini, 2012). These pathways are particularly relevant for maintaining brain 
homeostasis, as dysfunction of the endolysosomal and auto-phagic pathways has been 
associated with common neurodegenerative diseases, such as Alzheimer and Parkinson 
(Fraldi et al., 2016; Laplante and Sabatini, 2012), and lysosomal storage disorders—a group 
of inherited disorders characterized by the intralysosomal buildup of partially degraded 
metabolites, including cholesterol (Castellano et al., 2017; Schulze and Sandhoff, 2011).
Increasingly, dysregulation of cholesterol homeostasis is proposed as a contributing factor in 
the development of neurodegenerative disorders (Abdel-Khalik et al., 2017; Chang et al., 
2017; Di Paolo and Kim, 2011; Eriksson et al., 2017). A main source of neuronal cholesterol 
is the internalization of cholesterol that is synthesized by glia. This import of cholesterol is 
predominantly mediated by astrocyte-derived apolipoprotein E (ApoE)-containing 
lipoprotein particles (Boyles et al., 1989; Herz and Bock, 2002). These lipoproteins are 
internalized via clathrin-mediated endocytosis and delivered to late lysosomal compartments 
where acidic lipases liberate cholesterol. The free cholesterol is transferred by the luminal 
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Niemann-Pick C2 protein to the membrane-bound Niemann-Pick type C1 (NPC1) protein 
for export to the endoplasmic reticulum (ER) by sterol transfer proteins (e.g., ORP5, 
ORPL1) at membrane contact sites between the ER and the lysosome (Du et al., 2011; 
Karten et al., 2009; Li et al., 2016; Luo et al., 2017; Zhao and Ridgway, 2017). The 
importance of the NPC1 protein in regulating the transfer of cholesterol to the ER is 
underscored by the severity of the fatal Niemann-Pick type C1 (NPC1) neurodegenerative 
disease. This autosomal recessive lysosomal storage disorder most commonly occurs due to 
a single I1061T substitution that results in misfolding of the NPC1 protein and subsequent 
targeting for ER-associated degradation (Gelsthorpe et al., 2008). The reduction in 
functional NPC1 protein results in massive luminal accumulation of cholesterol in 
lysosomes and cellular changes in cholesterol homeostasis (Millard et al., 2000). 
Neurologically, NPC1 patients typically exhibit progressive impairment of motor and 
intellectual function, before succumbing to the disease, tragically within the first 2 decades 
of life (Vanier, 1999). Despite the commonality of altered cholesterol metabolism and 
compromised neuronal function in neurodegenerative disorders, the molecular mechanisms 
that link cellular changes in cholesterol with alterations in neuronal excitability are absent. 
Thus, this monogenetic disease, with such profound alterations in cholesterol metabolism, 
allows us to test the hypothesis that altered lysosomal cholesterol metabolism can change the 
intrinsic electrical excitability of neurons (Figure 1A).
Neuronal excitability depends on the proper function of ion channels whose activities can be 
tuned by plasma membrane (PM) lipids, including cholesterol and the minor 
phosphoinositide, phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P2). PtdIns(4,5)P2 
regulates upward of 100 ion channels and transporters (Hilgemann et al., 2001; Hille et al., 
2015), while cholesterol commonly suppresses the activity of several types of channels, 
including inwardly rectifying K+ channels (Romanenko et al., 2004), Ca2+-sensitive K+ 
channels (Bukiya et al., 2011; Crowley et al., 2003; Purcell et al., 2011), and voltage-gated 
K+ channels (Abi-Char et al., 2007; Hajdú et al., 2003). Despite separate biosynthetic 
pathways, the metabolism of cholesterol and phosphoinositides is not as distinct as 
previously thought. The transport of cholesterol between intracellular membranes at 
membrane contact sites uses phosphoinositides as the driving force to transport cholesterol 
(Mesmin et al., 2013). Another link between cholesterol and phosphoinositide metabolism 
involves the ABCA1 cholesterol transporter, which has been reported as being a 
PtdIns(4,5)P2 floppase (exports PtdIns(4,5)P2 out of the cell) (Gulshan et al., 2016). Hence, 
alterations in the cholesterol content of organelle membranes could dysregulate ion channel 
activity directly or indirectly by modifying PtdIns(4,5)P2.
Here, we find that both pharmacological inhibition of NPC1 and its genetic mutation in an 
established transgenic animal model of the disease render neurons hyperexcitable. 
Furthermore, we discover that reduced KCNQ2/3 current density underlies this electrical 
hyperexcitability, which is mediated by a significant reduction in the abundance of PM 
PtdIns(4,5)P2. The molecular mechanism that leads to a reduction in PtdIns(4,5)P2 in NPC1 
disease is a sterol regulatory element-binding protein (SREBP)-dependent upregulation of 
ABCA1. These data support the hypothesis that the regulated efflux of cholesterol from 
lysosomal membranes via NPC1 continually aids in the regulation of neuronal excitability 
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and reveals a link between lysosomal cholesterol and phosphoinositide metabolism in NPC1 
disease. This link could have broad implications for other neurodegenerative disorders.
RESULTS
Pharmacological Inhibition of NPC1 Increases Neuronal Excitability
NPC1 disease cells exhibit a characteristic accumulation of cholesterol in lysosomes 
(Gelsthorpe et al., 2008; Millard et al., 2000; Yu et al., 2005). This cellular phenotype has 
become useful in the diagnosis of NPC1 disease since it is readily identifiable following 
staining with the naturally fluorescent polyene antibiotic, filipin (Vanier and Latour, 2015). 
Figure 1B presents confocal micrographs of filipin-stained fibroblasts isolated from healthy 
and NPC1 patients carrying the most prevalent mutation (NPC1I1061T) (Millat et al., 1999; 
Park et al., 2003). Analysis of these images revealed that NPC1I1061T fibroblasts have larger 
cholesterol-containing vesicles (Figure 1C), with the median vesicle size of healthy 
fibroblasts being 0.22 μm2 (Q1 = 0.13 μm2 and Q3 = 0.39 μm2) and NPC1I1061T fibroblasts 
being 0.38 μm2 (Q1 = 0.18 μm2 and Q3 = 0.75 μm2). To mimic the cholesterol accumulation 
phenotype of NPC1 disease in isolated neurons, we used the well-characterized NPC1 
inhibitor U18666A (U18; 1 μM). This cationic amphiphile directly binds to the sterol-
sensing domain of the NPC1 protein (Lu et al., 2015) and blocks the efflux of cholesterol 
from lysosomes (Lange et al., 2000), thereby mimicking NPC1 disease. Cultured 
sympathetic (Figures 1D and 1E) or hippocampal (Figure S1A) neurons were treated 
overnight in the presence of U18 and stained with filipin. Similar to NPC1I1061T patient 
fibroblasts, U18 treatment induced the accumulation of cholesterol within vesicles (Figures 
1D and 1E). While the median vesicle size of neurons cultured without U18 (control) was 
0.03 μm2 (Q1 = 0.01 μm2 and Q3 = 0.12 μm2), the median vesicle size of neurons cultured 
in the presence of U18 was 0.11 μm2 (Q1 = 0.02 μm2 and Q3 = 0.49 μm2). Thus, treatment 
of neurons with U18 mimics the accumulation of cholesterol observed in fibroblasts from 
NPC1I1061T patients and represents a pharmacological tool to dissect the role of lysosome 
cholesterol efflux in regulating neuronal function.
To test whether U18-induced cholesterol accumulation alters neuronal excitability, action 
potentials (APs) were recorded in current-clamp mode using the perforated-patch 
configuration. Figure 1F shows recordings from a representative neuron cultured in the 
absence of U18 (control). Here, injecting 40 pA elicits a solitary AP despite the depolarizing 
stimulus being applied for 1 s (black trace). This typical firing pattern of sympathetic 
neurons corresponds to the cell adapting to the stimulus (spike adaptation) (Brown and 
Passmore, 2009; Zaika et al., 2006). In striking contrast, the same stimulus induced the 
firing of 9 APs in a neuron cultured in the presence of U18 (Figure 1F, U18, black trace). We 
interpreted this result as a loss of spike adaptation. From these data it is also noticeable that 
the neuron cultured in the presence of U18 fired more APs per unit of injected current (e.g., 
20 pA, red trace) compared to the control neuron. To quantify changes in excitability, we 
measured the following: (1) the resting membrane potential (Vrest), (2) the amount of current 
injected necessary to elicit at least 1 AP (loosely called here rheobase), and (3) the number 
of APs fired with increasing current injections. Neurons cultured in the presence of U18 had 
a 9 mV more depolarized Vrest (Figure 1G, control: −59 ± 2 mV, U18: −50 ± 2 mV), 
Vivas et al. Page 4
Cell Rep. Author manuscript; available in PMC 2019 June 06.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
required less current injection to induce AP firing (Figure 1H, control: 37 ± 5 pA, U18: 17 
± 4 pA), and fired more APs per picoampere of current injected (Figure 1I). These U18-
mediated alterations in AP firing could also be recapitulated in cultured hippocampal 
neurons (Figures S1B and S1C). In conclusion, inhibiting NPC1-mediated cholesterol egress 
from the lysosome leads to neurons becoming more excitable.
NPC1I1061T Disease Neurons Are Hyperexcitable
Overnight application of U18 has been used extensively to investigate cellular changes in 
NPC1 disease. Despite its utility in doing so, this inhibition is acute relative to the chronic 
changes that occur during disease development in patients. Accordingly, the changes in 
electrical activity described above could represent transient changes in excitability observed 
when NPC1 is inhibited for hours; but over longer periods, neurons may adapt to restore 
their excitability. Therefore, to test whether neurons were also hyperexcitable in conditions 
closer to those of patients suffering from NPC1 disease (Figure 2A), we isolated neurons 
from a recently developed NPC1I1061T knockin murine model (Praggastis et al., 2015). 
Figure 2B shows micrographs of filipin-stained neurons isolated from NPC1I1061T mice 
compared to littermate WT controls. Similar to patient fibroblasts and U18-treated neurons, 
NPC1I1061T neurons exhibit an enhanced accumulation of cholesterol within vesicular 
structures, with the distribution of vesicle size shifted toward larger vesicles in NPC1I1061T 
neurons. While the median vesicle size in neurons from WT mice was 0.01 μm2 (Q1 = 0.01 
μm2 and Q3 = 0.08 μm2), the median vesicle size in neurons from NPC1I1061T mice was 
0.12 μm2 (Q1 = 0.02 μm2 and Q3 = 0.34 μm2). Next, we measured AP firing in WT and 
NPC1I1061T neurons. Figure 2D contrasts the electrical responses from representative 
neurons of each group. Comparable to what was observed following NPC1 inhibition, a 40-
pA current injection induced the firing of a solitary AP in WT neurons, whereas the same 
injection stimulus produced 9 APs to fire from an NPC1I1061T neuron. Analysis of neuronal 
electrical properties revealed that NPC1I1061T neurons had an 8-mV more depolarized Vrest 
(Figure 2E, WT: −56 ± 1 mV, n = 20; NPC1I1061T: −48 ± 2 mV), required less current to 
induce AP firing (Figure 2F, WT: 29 ± 4 pA; NPC1I1061T: 14 ± 2 pA), and fired a greater 
number of APs per picoampere of current injected (Figure 2G, 100 pA; WT: 4 ± 1 AP; 
NPC1I1061T: 16 ± 2 APs). These results show that the most prevalent NPC1 disease-causing 
mutation renders neurons hyperexcitable, suggesting a common mechanism that relates 
lysosomal cholesterol transport to the ability of neurons to send and receive electrical inputs.
Loss of NPC1 Function Reduces KCNQ2/3 Current (IKCNQ2/3)
Based on the significant changes in neuronal firing behavior, we hypothesized that 
KCNQ2/3 voltage-gated potassium channel (KV 7.2/7.3) current density may be altered in 
NPC1 disease (Figure 3A). Our rationale follows: (1) KCNQ2/3 channels activate at 
negative potentials (~−65 mV) and thus help establish Vrest, (2) KCNQ2/3 channels open in 
response to depolarization to repolarize the membrane potential, and (3) KCNQ2/3 channels 
participate in spike frequency adaptation (Brown and Passmore, 2009). Thus, reduced 
IKCNQ2/3 is expected to depolarize Vrest increase intrinsic electrical excitability, and decrease 
spike frequency adaption—all electrophysiological consequences observed in NPC1 disease 
neurons. Consequently, we measured IKCNQ2/3 densities from U18-treated, NPC1I1061T, and 
NPC1−/− neurons. IKCNQ2/3 density was smaller following the inhibition of NPC1 (Figures 
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3B and 3C, 1.8 ± 0.3 pA/pF) compared to control neurons (5.9 ± 0.8 pA/pF). This reduction 
in IKCNQ2/3 density was not observed following a 2-min acute application of the inhibitor, 
ruling out a direct inhibition or block of the channel (Figure S2). Furthermore, IKCNQ2/3 
density was also smaller in neurons from NPC1I1061T mice (Figures 3D and 3E, WT: 9.0 
± 1.0 pA/pF; NPC1I1061T: 4.2 ± 0.8 pA/pF) and NPC1−/− mice (Figures 3F and 3G, WT: 6.8 
± 0.8 pA/pF; NPC1−/−: 2.9 ± 0.4 pA/pF). Consequently, inhibition, deletion, or disease-
causing mutation of the NPC1 cholesterol transporter reduce IKCNQ2/3 density and offer a 
potential mechanism underlying the hyperexcitability phenotype in NPC1 disease.
Opening KCNQ2/3 Channels Rescues NPC1I1061T Neuron Excitability
Following the premise that the reduction of IKCNQ2/3 leads to a hyperexcited state in neurons 
with non-functional NPC1, we predicted that the application of retigabine, a KCNQ2/3 
channel opener (Gunthorpe et al., 2012), would make them less excitable (Figure 4A). Bath 
application of 10 mM retigabine quickly and reversibly restored the normal firing behavior 
of U18-treated neurons (Figures 4B–4E), with fewer APs recorded per picoampere of 
current injected (100 pA; U18 treated: 19 ± 1 AP; with retigabine: 3 ± 2 APs; washout: 18 
± 1 APs; n = 8, p < 0.0001 for U18 versus retigabine; p = 0.5 for U18 versus washout; and p 
< 0.0001 for retigabine versus washout). Retigabine was also effective at abrogating the 
hyperexcited state of NPC1I1061T neurons (Figure 4F, 100 pA; NPC1I1061T: 16 ± 2 APs; 
NPC1I1061T + retigabine: 8 ± 3). These results support the hypothesis that a reduction in 
IKCNQ2/3 density is responsible for the enhanced excitability observed in NPC1 disease 
neurons.
PM PtdIns(4,5)P2 Is Reduced in NPC1 Disease
We next asked what mechanism underlies the reduction in IKCNQ2/3. First, we ruled out the 
possibility that KCNQ channel abundance was altered in NPC1 disease (Figure S3). Then, 
we tested the hypothesis that PtdIns(4,5)P2 is altered in NPC1 disease. PtdIns(4,5)P2 is the 
most abundant phosphoinositide at the PM and is absolutely required for KCNQ2/3 channel 
function (Suh and Hille, 2002; Zhang et al., 2003); hence, any reductions in PtdIns(4,5)P2 
could lead to reduced IKCNQ2/3 (Figure 5A). To determine whether PtdIns(4,5)P2 is altered 
in NPC1 disease, we took two approaches: expression of a fluorescently tagged, genetically 
encoded PtdIns(4,5)P2 biosensor (yellow fluorescent protein [YFP]-pleckstrin homology 
domain [PH]PLCδ1) and ultrahigh pressure liquid chromatography coupled to tandem mass 
spectrometry (UPLC-MS/MS). We chose these two complementary approaches because 
UPLC-MS/MS is extremely quantitative but does not distinguish specific PtdInsP2 
regioisomers (i.e., PtdIns(3,5)P2 versus PtdIns(4,5)P2), whereas the imaging approach is 
semiquantitative but offers spatial information and is excellent at differentiating specific 
regioisomers. Analysis of healthy and NPC1I1061T patient fibroblasts transfected with YFP-
PHPLCδ1 revealed a decrease in the ratio of fluorescence intensity at the PM compared to the 
cytoplasm (Cyt) in NPC1I1061T patient fibroblasts (Figures 5B and 5C; WT: 4.0 ± 0.2, n = 
21; NPC1I1061T: 2.8 ± 0.2). In addition, MS showed a 50% reduction in total PtdInsP2 in 
NPC1I1061T fibroblasts (Figure 5D; WT: 2.3 × 106 ± 0.6 × 105; NPC1I1061T: 1.2 × 106 ± 0.8 
× 105). To further test this hypothesis, we also measured PtdInsP2 levels from three different 
brain regions (hippocampus, cortex, and cerebellum) of NPC1I1061T mice and found similar 
reductions in PtdInsP2 across each region (Figures 5E–5H ), with total PtdInsP2 reduced by 
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66% (Figure 5I; WT = 6.6 × 107 ± 0.9 × 107; NPC1I1061T = 2.5 × 107 ± 0.7 × 107). These 
results indicate that PtdIns(4,5)P2 is reduced in NPC1 disease and offers an underlying 
mechanism for the reduction of IKCNQ2/3 and neuron hyperexcitability.
Exogenous Application of PtdIns(4,5)P2 Rescues Both IKCNQ2/3 and Excitability
Following the premise that neurons lacking functional NPC1 have less PtdIns(4,5)P2 and 
consequently reduced IKCNQ2/3 and increased excitability, we next asked whether exogenous 
dialysis of PtdIns(4,5)P2 would increase IKCNQ2/3 and rescue excitability in U18-treated 
neurons (Figure 6A). Patch-clamp electrophysiology was performed in whole-cell mode 
with pipettes filled with a standard internal solution or a solution supplemented with 30 μM 
diC8-PtdIns(4,5)P2. Figure 6B shows representative recordings of IKCNQ2/3 from control 
neurons patched with or without diC8-PtdIns(4,5)P2. The addition of diC8-PtdIns(4,5)P2 to 
the cell through the patch pipette did not change the current density in control neurons 
(Figure 6D, without diC8-PtdIns(4,5)P2: 10.9 ± 2.0 pA/pF; with diC8-PtdIns(4,5)P2: 7.8 
± 1.5 pA/pF). However, the addition of diC8-PtdIns(4,5)P2 significantly increased IKCNQ2/3 
density in neurons cultured in the presence of U18 (8.4 ± 1.3 pA/pF) compared to neurons 
cultured in the presence of U18 alone (2.4 ± 0.9 pA/pF; Figures 6C and 6D). IKCNQ2/3 
density was not statistically different between control neurons and U18-treated neurons 
following the application of diC8-PtdIns(4,5)P2, suggesting that the exogenous addition of 
PtdIns(4,5)P2 rescues IKCNQ2/3 in neurons lacking functional NPC1. Finally, we tested 
whether the addition of 30 μM diC8-PtdIns(4,5)P2 rescues the excitability of neurons with 
inhibited NPC1. Figure 6E shows representative current-clamp recordings of U18 neurons 
treated with or without diC8PtdIns(4,5)P2. Note that the addition of diC8-PtdIns(4,5)P2 to 
neurons caused fewer APs to fire following a 40 pA current injection (1 AP, black trace) 
compared to a neuron cultured in the presence of U18 but patched without diC8-
PtdIns(4,5)P2 (9 APs, black trace). In fact, neurons patched with diC8PtdIns(4,5)P2 fired 
fewer APs with every current injection tested, reaching a maximum of 5 ± 2 APs when 
neurons were stimulated with 100 pA current injection (n = 8), compared to 13 ± 3 APs 
when neurons were patched without PtdIns(4,5)P2 (Figure 6F). In conclusion, exogenous 
application of diC8-PtdIns(4,5)P2 to neurons lacking functional NPC1 is enough to rescue 
the hyperexcitable phenotype, supporting the hypothesis that these neurons have less 
PtdIns(4,5)P2 and that the reduction of this lipid is the underlying mechanism of 
hyperexcitability in NPC1 disease.
Upregulation of ABCA1 Reduces PtdIns(4,5)P2, Leading to Hyperexcitability in NPC1 
Disease
Finally, we sought to determine the molecular link between the accumulation of cholesterol 
in the lysosome and the reduction of PtdIns(4,5)P2 at the PM. A striking consequence of 
disrupting NPC1-dependent cholesterol efflux is the activation of SREBP, a transcription 
factor that controls the synthesis of cholesterol and other membrane lipids (Brown and 
Goldstein, 1997). This transcription factor not only controls cholesterol synthesis through an 
end product feedback mechanism but it also controls many other physiological processes. 
For instance, the overexpression of SREBP in myocytes changes the expression of ~1,500 
genes (Rome et al., 2008). Considering the significant number of protein-coding genes under 
the control of SREBP, we tested whether crucial enzymes related to PtdIns(4,5)P2 
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metabolism are altered in NPC1 disease (Figure 7A). To begin, we verified that the 
activation of SREBP, independent of NPC1 function, reduced PM PtdIns(4,5)P2 (Figure S4). 
Next, determination of the protein abundances of PIP5K1A (phosphatidylinositol 4-
phosphate 5-kinase type 1A), SYNJ1 (Synaptojanin 1), and PLCβ1 (phospholipase C β1) 
revealed no significant difference between healthy and NPC1I1061T (Figures 7B and 7C). 
Therefore, we ruled out the misregulation of any of these three important proteins as a 
possible mechanism for the reduction of PtdIns(4,5)P2 in NPC1 disease.
Given that phosphoinositide lipid kinases or lipid phosphatases do not appear to underlie the 
reduction in PM PtdIns(4,5)P2, we focused our attention on proteins that are key regulators 
of the transport of both cholesterol and phosphoinositide metabolism. To this end, we tested 
whether several known phosphoinositide transfer proteins (ORP2, ORPL1, ORP5/8) or the 
ABCA1 (ATP-binding cassette transporter-A1) transporter are differentially expressed in 
NPC1 disease. Oxysterol-binding protein (OSBP)-related proteins are transfer proteins that 
transfer cholesterol at membrane contact sites through the counter-transport of PtdIns4P and 
PtdIns(4,5)P2 (Ghai et al., 2017; Mesmin et al., 2013; Wang et al., 2019; Zhao and Ridgway, 
2017), whereas ABCA1 (ATP-binding cassette transporter-A1) is a transmembrane protein, 
which plays a major role in lipid homeostasis by regulating cholesterol efflux from the cell. 
In addition, ABCA1 has been recently reported to exhibit PtdIns(4,5)P2 floppase activity, 
moving PtdIns(4,5)P2 from the inner leaflet to the outer leaflet of the PM to mediate Apo1-
dependent binding during nascent high-density lipoprotein (HDL) assembly (Gulshan et al., 
2016). Determination of protein abundances revealed that the average fold change of ORP2 
was 1.35 ± 0.05 (n = 3, p = 0.0004), ORPL1 was 1.33 ± 0.06 (n = 4, p = 0.002), ORP8 was 
1.16 ± 0.25 (n = 4, p = 0.5), and ABCA1 was 3.3 ± 0.3 (n = 4, p = 0.002) in NPC1I1061T 
fibroblasts (Figures 7I and S5). Thus, in NPC1 disease, several key phosphoinositide transfer 
proteins are differentially expressed. The fold change of OPR2 and ORPL1 is small 
compared to the >3-fold increase in ABCA1 abundance; therefore, we focused our attention 
on determining whether ABCA1 is responsible for reducing PtdIns(4,5)P2, PtdIns(4,5)P2-
dependent ion channel current, and excitability in NPC1 disease.
To test for the involvement of ABCA1 in altering PtdIns(4,5)P2, we took two 
complementary approaches that, independently of NPC1 function, increase the abundance of 
ABCA1. First, we treated healthy patient fibroblasts or neurons with an agonist of the 
nuclear liver factor receptor (LXR) T0901317 (Figures 7E, 7F, and S6), which upregulates 
the expression of ABCA1. Second, we used a cell line that stably expresses the ABCA1 
transporter at a high copy number (Figures 7G and 7H). Under both experimental 
conditions, there was a lower PM-to-Cyt fluorescence intensity ratio of the PtdIns(4,5)P2 
biosensor (PHPLCδ1), suggesting reduced PtdIns(4,5)P2. Next, we tested the hypothesis that 
blocking ABCA1 rescues both IKCNQ2/3 and excitability in NPC1 disease (Figure 7J). To 
block ABCA1, we added 10 μM probucol to neurons that were isolated from NPC1I1061T 
mice. Blocking ABCA1 increased IKCNQ2/3 density in NPC1I1061T neurons from 1.8 ± 0.5 
to 6.4 ± 1.1 pA/pF (Figure 7K, p = 0.005). Moreover, neurons from NPC1I1061T mice treated 
with probucol fired 6.5 ± 1.7 APs with 100 pA current injection and exhibited more spike 
adaptation (Figure 7L, n = 9), meaning that they were less excitable than neurons from 
NPC1I1061T mice (compare data from Figure 2G). Finally, treating U18 neurons with small 
interfering RNA (siRNA) directed against ABCA1 increased IKCNQ2/3 current density, 
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restored the resting membrane potential, and rescued excitability (Figure S7). These data 
suggest that the loss of NPC1 function indirectly alters the level of proteins that transport 
both cholesterol and PtdIns(4,5)P2, leading to decreased PM PtdIns(4,5)P2, decreased 
IKCNQ2/3, and, consequently, enhanced excitability.
DISCUSSION
Here, we show for the first time that both inhibition and disease-causing mutation of the 
lysosomal cholesterol transporter, NPC1, render neurons hyperexcitable, in that neurons 
have a more depolarized Vrest, less current is required to induce them to fire APs, and they 
lose the ability to complete spike adaptation. Changes in excitability result from reduced PM 
PtdIns(4,5)P2 and the subsequent reduction of KCNQ2/3 channel function. Furthermore, the 
molecular mechanism that links cholesterol accumulation and PtdIns(4,5)P2 reduction is the 
upregulation of ABCA1. Based on these data, we propose that NPC1 disease is a 
phosphoinositide-deficient disease and that ABCA1 links lysosomal cholesterol efflux with 
PM phosphoinositide levels to tune neuronal excitability.
PtdIns(4,5)P2 Deficiency Underlies Neuronal Hyperexcitability in NPC1 Disease
Like many monogenetic disorders, despite the seemingly nondescript nature of a single 
mutation, the mechanisms of NPC1 pathogenesis are complicated. For NPC1 disease, 
>1,500 genes (Rome et al., 2008) and ~300 proteins (Rauniyar et al., 2015) are differentially 
regulated. At the cellular level, these alterations manifest as defects in vesicular trafficking, 
mTOR signaling (Castellano et al., 2017), lysosomal calcium handling (Lloyd-Evans et al., 
2008), and lipid localization (Lloyd-Evans et al., 2008; Praggastis et al., 2015). We report 
for the first time hyperexcitability in NPC1 disease. Evidence presented in this study 
suggests that the mechanism underlying this enhanced excitability is a reduction in IKCNQ2/3 
mediated by a decline in PtdIns(4,5)P2. Could other lipids altered in NPC1 disease, such as 
cholesterol or sphingolipids, account for the reduction in IKCNQ2/3? For cholesterol, 
KCNQ2/3 channels are reported as being negatively regulated by PM cholesterol (Lee et al., 
2010). In cells lacking functional NPC1, there is a described reduction in the amount of 
cholesterol in the endofacial leaflet of the PM (Maekawa and Fairn, 2015). Thus, decreased 
PM cholesterol in NPC1 disease would disinhibit KCNQ2/3 channels and result in more 
current, which is the opposite of our observations. Another lipid that accumulates in 
lysosomes in NPC1 disease is sphingosine-1-phosphate (S1P) (Praggastis et al., 2015). 
Some reports show that KCNQ2/3 channel activity can be weakly stimulated (increase in 
channel open probability [Po] to 0.16) by a high concentration (100 μM) of S1P (Telezhkin 
et al., 2012). In contrast, a lower concentration (10 μM) of PtdIns(4,5)P2 is enough to 
activate KCNQ2/3 channels with a Po of 0.54. Therefore, if S1P is reduced in the PM of 
NPC1 disease neurons, it would be anticipated that the differences in affinity that KCNQ2/3 
has for each lipid would mean that any S1P effects would be secondary to PtdIns(4,5)P2-
dependent alterations. In conclusion, decreases in either cholesterol or S1P appear unlikely 
to account for the reductions of IKCNQ2/3 in NPC1 disease.
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Cholesterol and PtdIns(4,5)P2 Dysregulation in Neurodegenerative Diseases
We present evidence linking the disruption of lysosomal cholesterol efflux with decreases in 
PtdIns(4,5)P2-dependent KCNQ2/3 channel activity, leading to aberrant neuronal activity. At 
the molecular level, our data suggest that the cholesterol transporter and PtdIns(4,5)P2 
floppase, ABCA1, is responsible for the decline in PtdIns(4,5)P2 that consequently modifies 
the electrical properties of NPC1 disease neurons. Fibroblasts from patients with Tangier 
disease, a disease caused by mutations in ABCA1, transfer 50% less PtdIns than fibroblasts 
from healthy patients (von Eckardstein et al., 1998), while mutations in ABCA1 have been 
associated with a higher risk of Alzheimer disease (Nordestgaard et al., 2015). Thus, there is 
a precedent for the involvement of ABCA1 as a potential contributing factor in 
neurodegeneration. Is there evidence in the literature to suggest that other neurodegenerative 
diseases have either dysfunction of KCNQ2/3 channel activity or altered levels of 
PtdIns(4,5)P2? In fact, there is accumulating evidence that mutations in the genes encoding 
KCNQ2/3 subunits or PtdIns(4,5)P2-metabolizing enzymes lead to neuropathies similar to 
those in NPC1 disease. Mutations in KCNQ2/3 cause the hyperexcitability of neurons, 
leading to epileptic phenotypes in neonatal epilepsy (Jentsch, 2000; Watanabe et al., 2000), 
Huntington disease (Cao et al., 2015), and the bulbar form of amyotrophic lateral sclerosis 
(ALS) (Ghezzi et al., 2018). Opening KCNQ2/3 channels with retigabine protects 
motoneurons against the excitotoxicity characteristic of this form of ALS (Ghezzi et al., 
2018). Further, mutations in the enzymes responsible for PtdIns(4,5)P2 synthesis are 
associated with Alzheimer disease (Zhu et al., 2015), Parkinson disease (Cao et al., 2017), 
and Friedreich ataxia (Bayot et al., 2013), another rare neurodegenerative disease. These 
data support the idea that maintaining PtdIns(4,5)P2 levels in neurons is essential for normal 
brain function and that dysfunction of KCNQ2/3 channel activity may be a contributing 
factor to the progression of neurodegenerative diseases. It is important to note that the 
relationship between enhanced neuronal excitability and neurodegeneration in NPC1 disease 
is correlative at this point. Given the fundamental importance of regulated ion channel 
function and Ca2+ homeostasis for neuron health and the Ca2+ hypothesis of 
neurodegeneration, which posits that altered Ca2+ dynamics contribute to neuropathology 
(Berridge, 2010), we hypothesize that alterations in the excitability alluded to above would 
facilitate enhanced Ca2+ influx into cerebellar neurons, potentially leading to their 
degeneration in NPC1 disease. Future experiments are needed to establish causation between 
hyperexcitability and cell death in NPC1 disease.
To conclude, mutations within the NPC1 protein lead to a poorly understood sequence of 
events that end in neurodegeneration and premature death. We have defined steps in the 
pathogenic cascade of NPC1 disease, namely upregulation of ABCA1 leading to a decrease 
in PM PtdIns(4,5)P2 and IKCNQ2/3, which produces hyperexcitability in neurons. Thus, 
NPC1 disease is not only a cholesterol storage disease but also a phosphoinositide-deficient 
disorder with a hyperexcitability phenotype.
STAR⋆METHODS
Detailed methods are provided in the online version of this paper and include the following:
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CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and reagents should be directed to and will be 
fulfilled by the Lead Contact, Eamonn J. Dickson (ejdickson@ucdavis.edu).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Murine models of NPC1 disease—NPC1 knock-out (NPC−/−, RRID: IMSR_JAX:
003092), NPC1I1061T knock-in (Praggastis et al., 2015), and wild-type (WT) mice from a 
C57BL/6 background were kindly provided by Daniel Ory (Washington University Saint 
Louis). Male C57BL/6 WT mice used for experiments involving U18666A (U18, SIGMA, 
Cat # 662015) were purchased from the Jackson Laboratory (RRID: IMSR_JAX:000664). 
All animals were kept in an animal facility with controlled conditions and were given 
standard chow and water ad libitum. The animal handling protocol was approved by the 
University of California Institutional Animal Care and Use Committee. To genotype 
NPC1I1061T mice, we extracted DNA and amplified an NPC1 allele with the following 
primers: forward (5′-tgatctgcacacttggaaccgag-3′) and reverse (5′-
cactgccttgagcagcatctcag-3′). WT allele was identified by a 200 bp fragment, whereas the 
knock-in allele was identified by a 234 bp fragment. Heterozygous mice, containing both 
200 bp and 234 bp, were not used in this study. Experiments using either knock-out or 
knock-in animals were conducted using both males and females. Knock-out animals were 
used at around 70 days old. Knock-in animals were used at around 90 days old.
Cell lines—Fibroblast cell lines from a healthy male (GM05659, RRID: CVCL_7434) and 
a male patient with a homozygous mutation in NPC1I1061T (GM18453, RRID: 
CVCL_DA78, from the NIGMS repository) were purchased from the Coriell Institute. 
Fibroblasts were grown in Eagle’s Minimum Essential Medium (MEM) with Earle’s salts 
and non-essential amino acids (SIGMA, Cat # M5650) supplemented with 2 mM L-
glutamine (GIBCO, Cat # 25030–081), 15% non-inactivated fetal bovine serum (GIBCO, 
Cat # 26140–079) and 0.2% penicillin/streptomycin (GIBCO, Cat # 15140–122), passaged 
twice a week, and incubated in 5% CO2 at 37°C.
HeLa cells stably expressing ABCA1-GFP were provided by Dr. Alan Remaley, NHLBI, 
Bethesda, MD. HeLa cells were grown in DMEM (GIBCO, Cat # 11995–065) supplemented 
with 10% non-inactivated fetal bovine serum and 0.2% penicillin/streptomycin, passaged 
twice a week, and incubated in 5% CO2 at 37°C. Expression of ABCA1-GFP HeLa cells 
was induced by adding 150 μg/ml geneticin (GIBCO, Cat # 10131–035) and 200 μg/ml 
Hygromycin (Invitrogen, Cat # 10687010).
METHOD DETAILS
Neuron isolation—Neurons from superior cervical ganglion (SCG) were prepared from 
10 to 16 week-old female or male mice by enzymatic digestion following a standardized 
protocol for rats (Vivas et al., 2013) but reducing the amount of enzymes. Briefly, mice were 
anesthetized with pentobarbital sodium (VETONE, Cat # 501016) before extraction of the 
SCG. SCG were cleaned and sliced into 4 pieces. This tissue was transferred to a tube 
containing 10 U/ml papain (SIGMA, Cat # 4762) in Hank’s solution and kept at 37°C for 6 
min, then it was transferred to a solution containing 0.33 mg/ml collagenase type II 
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(Worthington, Cat # LS004176) and 2.5 mg/ml dispase (GIBCO, Cat # 0479) for up to 60 
min. Every 20 min the tissue was pipetted to dissociated into individual cells. After 
obtaining a homogeneous cell suspension, cells were washed with DMEM followed by 
centrifugation at 180 g for 3 min. Washing step was repeated 3 times. Isolated neurons were 
plated on poly-L-lysine (MW > 300,000, SIGMA, Cat # P5899) coated glass coverslips and 
incubated in 5% CO2 at 37°C in DMEM supplemented with 10% FBS and 0.2% penicillin/
streptomycin. Neurons were used up to 24 h after plating.
Filipin Staining and Super-resolution Imaging—Cells washed with PBS were fixed 
with a mix of 3% paraformaldehyde (Electron Microscopy Sciences, Cat # 15710) and 0.1% 
glutaraldehyde (SIGMA, Cat # G7651) for 10 min at 21°C. Following a 5-minute incubation 
with sodium borohydrate (10 mM, SIGMA, Cat #, 213462), cells were stained with 3 mg/ml 
filipin (SIGMA, Cat # F9765) for 2 h at room temperature. Cells were imaged in PBS. 
During the filipin staining process cells were protected from unnecessary light exposure. 
Cells were imaged using a Zeiss880 AiryScan microscope (axial resolution of 120 nm) by 
exciting with a 405 nm LED. This imaging mode allowed us to resolve cholesterol-
containing vesicles.
Electrophysiological Recordings—All electrophysiological recordings were 
performed at room temperature. Voltage responses were recorded using perforated-patch 
configuration (except Figure 6) in the current-clamp mode, whereas KCNQ2/3 current was 
recorded using the whole-cell configuration in voltage clamp mode. To isolate KCNQ2/3 tail 
currents, the voltage was held at −20 mV, before stepping to −60 mV. The amplitude of 
KCNQ2/3 currents was measured from the resulting currents relative to the current at the 
end of the pulse (current close to 0 pA). We used an Axopatch 200B amplifier coupled with 
an Axon Digidata 1550B data acquisition board (Molecular Devices Electrophysiology) to 
acquire the electrical signals. Patch pipettes had a resistance of 2 – 6 MΩ. Liquid junction 
potential of 4 mV was calculated using the pCLAMP 10 software and was not corrected for, 
hence the Vrest reported in the Results section is in fact 4 mV more negative (around −63 
mV in WT SCG neurons). Voltage responses were sampled at 5 KHz, whereas currents were 
sampled at 2 KHz. For current recordings, cell capacitance was cancelled out and series 
resistances of < 10 MΩ were compensated by 60%. Due to remaining series resistance, 
voltage error is expected to be < 4 mV. The bath solution (Ringer’s solution) contained 150 
mM NaCl, 2.5 mM KCl, 2 mM CaCl2, 1 mM MgCl2, 10 mM HEPES, and 8 mM glucose, 
adjusted to pH 7.4 with NaOH. The internal solution used to fill the patch pipettes contained 
175 mM KCl, 1 mM MgCl2, 5 mM HEPES, 0.1 mM K4BAPTA, 3 mM Na2ATP, and 0.1 
mM Na3GTP, adjusted to pH 7.2 with KOH. For current-clamp recordings, 30 μM 
amphotericin B (SIGMA, Cat # A4888) was added to the internal solution to facilitate 
electrical access to the cell. The bath solution was perfused at 2 ml/minute, permitting 
solution exchange surrounding the recording cell with a time constant of 4 s. DiC8-
PtdIns(4,5)P2 (30 μM, Avanti Polar Lipids, Cat # 850185) was added in the internal solution.
Protein extraction and abundance determination—Protein from cell cultures, SCG, 
or brain tissue was harvested in RIPA buffer (Thermo Scientific, Cat # 89900) with 
Complete, Mini, EDTA-free protease inhibitor cocktail (Roche, Cat # 11836170001) for 15 
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min at 4°C. For SCG and brain tissue, protein samples were sonicated using a bath sonicator 
at 4°C. Postnuclear supernatant was isolated by centrifuging for 20 minutes at 13,600 g at 
4°C. Protein concentration was quantified with a plate reader using the Pierce BCA protein 
assay kit (Thermo Scientific, Cat # 23225). Protein samples were resolved in 4%–12% Bis-
Tris gels under reducing conditions. Proteins were transferred onto nitrocellulose 
membranes (Life Technologies, Cat # LC2000) using the Mini-Bolt system (Thermo 
Scientific, Cat # A25977). Membranes were blotted using rabbit monoclonal anti-NPC1 
(Abcam, Cat # ab134113, RRID: AB_2734695, 1:1,000), rabbit anti-KCNQ2 (Abcam, Cat # 
ab22897, RRID: AB_775890, 1:500), mouse anti-ABCA1 (Abcam, Cat # ab18180, RRID: 
AB_444302, 1:1000), rabbit anti-PIP5K1A (Cell Signaling Technology, Cat # 9693, RRID: 
AB_2164698, 1:500), rabbit anti-SYNJ1 (SIGMA, Cat # HPA011916, RRID: AB_1857692, 
1:500), rabbit anti-PLCβ1 (Abcam, Cat # ab182359, 1:1000), and mouse anti-β-actin 
(Thermo Scientific, Cat # MA1–91399, RRID: AB_2273656, 1:10,000). Blotted bands were 
detected using fluorescent secondary antibodies goat anti-rabbit 680RD (P/N 926–68071, 
LI_COR biosciences, RRID: AB_10956389, 1:10,000) and goat anti-mouse 800CW (P/N 
925–32210, LI_COR biosciences, RRID: AB_2687825, 1:20,000). ImageJ was used to 
calculate fluorescence density of each band. The abundance of NPC1 or KCNQ2 from 
NPC1I1061T or U18-treated tissue was reported as normalized to β-actin and relative to the 
abundance in WT or control tissue.
Measuring PtdIns(4,5)P2—To measure PtdIns(4,5)P2 in fibroblasts, a plasmid for 
PHPLCδ1 tagged with YFP was transfected (0.2 μg DNA) using Lipofectamine LTX 
(Invitrogen, Cat # 11668–027). Imaging of this biosensor was performed 24 h post-
transfection using a spinning disk confocal microscope (Andor W-1 spinning disk). To 
measure PtdIns(4,5)P2 from fibroblasts and brain samples by mass spectrometry, lipids were 
extracted with butanol and chloroform, as described previously (Traynor-Kaplan et al., 
2017). A PtdIns(4,5)P2 standard was added 17:0, 20:4 PtdIns(4,5)P2 (Avanti Lipids, Cat # 
LM-1904) to all biological samples. Samples were neutralized by methylation and infused 
with sodium formate and analyzed using a Waters XEVO TQ-S MS/MS in multiple reaction 
monitoring mode (MRM) using electrospray and positive ion mode. Elution profiles plotting 
the intensity (arbitrary units) as a function of elution time (minutes) were analyzed to 
determine relative changes in PtdInsP2 levels between samples. Total integrated areas under 
peaks from samples and standards were quantified using MassLynx software (Waters, RRID: 
SCR_014271). Peak areas of PIP2 from the biological sample were normalized to the 
synthetic standard and further corrected for tissue amount using total protein.
QUANTIFICATION AND STATISTICAL ANALYSIS
We used IGOR Pro (IGOR Software, WaveMetrics, RRID: SCR_000325), Excel 
(Microsoft), and Prism (GraphPad, RRID: SCR_002798) to analyze data. ImageJ (RRID: 
SCR_003070) was used to process images. Data were collected from independent 
experiments from at least three mice and are presented as Mean ± SEM. For the super-
resolution data of vesicle size, the median, first (Q1), and third (Q3) quartiles instead of the 
mean was used given that the data were not normally distributed (Normality test in Prism). 
A non-parametric statistical test (Mann-Whitney Wilcoxon) was used to test for statistical 
significance between vesicle size in different conditions. All other statistical analyses 
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presented in this study were performed using parametric Student’s t test, considering p 
values < 0.05 as statistical significance. The number of cells used for each experiment is 
detailed in each figure legend.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Highlights
• Loss of NPC1 function causes neurons to become hyperexcitable
• Intrinsic hyperexcitability is triggered by reduced KCNQ2/3 current
• Decrease of KCNQ2/3 current in NPC1 disease is caused by a reduction in 
PtdIns(4,5)P2
• Loss of PtdIns(4,5)P2 in NPC1 disease occurs due to upregulation of the 
ABCA1 transporter
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Figure 1. Pharmacological Inhibition of NPC1 Increases Neuronal Excitability
(A) Schematic of the hypothesis: lysosomal cholesterol efflux regulates neuron excitability.
(B) Inverted confocal micrographs of healthy (left) and NPC1I1061T (right) fibroblasts fixed 
and stained with filipin. Insets show the accumulation of cholesterol within the lysosome 
lumen.
(C) Comparison of normalized cumulative frequencies of vesicle size between healthy 
(black, 16 cells, 777 vesicles) and NPC1I1061T (red, 14 cells, 545 vesicles) fibroblasts. *p < 
0.0005, Mann-Whitney-Wilcoxon test.
(D) Inverted confocal micrographs of control (left) and U18-treated (right; 1 μM, 18 h) 
sympathetic neurons fixed and stained with filipin.
(E) Comparison of normalized cumulative frequencies of vesicle size between neurons 
cultured without (black, 17 cells, 2,186 vesicles) and with (red, 20 cells,1,373 vesicles, *p < 
0.0005, Mann-Whitney-Wilcoxon test) U18.
(F) Top: schematic of current injection protocol. Membrane potential was held at −65 mV, 
and current steps were given from −40 to 100 pA in 10-pA steps. Center: voltage traces from 
control neuron. Bottom: voltage traces from U18-treated neuron. Note that the U18-treated 
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neuron fires several APs with 40 pA current injection (bottom, black trace, 9 APs) compared 
to a neuron cultured without U18 (middle, black trace, 1 AP). Dotted lines: −65 mV.
(G) Summary of Vrest measured from neurons cultured without (empty circles, n = 8) and 
with (red circles, n = 8) U18.
(H) Quantification of the amount of current required to fire at least 1 AP (rheobase) in 
control (empty circles, n = 8) and U18-treated (red circles, n = 8) neurons.
(I) Comparison of the number of APs induced with increasing current injections in control 
(empty circles, n = 8) and U18-treated (red circles, n = 8) neurons. In all figures, average 
data are presented as mean ± SEM. See also Figure S1.
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Figure 2. NPC1I1061T Disease Neurons Are Hyperexcitable
(A) Schematic of the hypothesis: NPC1I1061T disease neurons are hyperexcitable.
(B) Inverted confocal micrographs of WT (left) and NPC1I1061T (right) mouse sympathetic 
neurons fixed and stained with filipin to show the accumulation of cholesterol.
(C) Comparison of normalized cumulative frequencies of vesicle size between wild-type 
(WT; black, 28 cells, 1,688 vesicles) and NPC1I1061T (red, 24 cells, 1,043 vesicles, *p < 
0.0005, Mann-Whitney-Wilcoxon test) neurons.
(D) Top: schematic of current injection protocol. Center: WT neuron fires 1 AP in response 
to 40 pA current injection (black trace). Bottom: NPC1I1061T neuron fires several APs with 
40 pA current injection (black trace, 9 APs). Dotted lines: −65 mV.
(E) Summary of Vrest measured from WT (empty circles, n = 20) or NPC1I1061T (red circles, 
n = 18) neurons.
(F) Histogram comparing the rheobase in WT (empty circles, n = 20) and NPC1I1061T (red 
circles, n = 18) neurons.
(G) Comparison of the number of APs induced with increasing current injections in WT 
(empty circles, n = 20) and NPC1I1061T (red circles, n = 18) neurons.
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Figure 3. Loss of NPC1 Function Reduces IKCNQ2/3
(A) Schematic of the hypothesis: reduction in IKCNQ2/3 underlies NPC1I1061T 
hyperexcitability.
(B) Comparison of IKCNQ2/3 recordings from neurons cultured overnight without (control) 
or with 1 μM U18. Arrow points toward the tail current, which was used to measure 
KCNQ2/3 current amplitude.
(C) Summary of IKCNQ2/3 amplitude normalized to cell size from control (n = 16) and U18-
treated (n = 11) neurons.
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(D) IKCNQ2/3 recordings from neurons isolated from WT or NPC1I1061T mice.
(E) Summary of IKCNQ2/3 density from WT(n = 12) and NPC1I1061T (n =12) neurons.
(F) IKCNQ2/3 recordings from neurons isolated from WT or knockout mice for NPC1 
(NPC1−/−).
(G) Summary of IKCNQ2/3 density from WT (n = 11) and NPC1−/− (n = 12). Dotted lines in 
(B), (D), and (F): 0 pA.
See also Figure S2.
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Figure 4. Opening KCNQ2/3 Channels Rescues NPC1I1061T Neuron Excitability
(A) Schematic of the hypothesis: opening KCNQ2/3 channels rescues NPC1I1061T 
hyperexcitability.
(B) Top: schematic of current injection protocol. Family of voltage recordings from a neuron 
treated overnight with 1 μM U18 (black trace, 7 APs).
(C) Family of voltage recordings from the same neuron as in (B), but after the application of 
10 μM retigabine (Rtg; black trace, 1 AP).
(D) Family of voltage recordings from the same neuron as in (B) and (C) following 3 min of 
retigabine washout (black trace, 9 APs). Dotted lines in (B), (C), and (D): −65 mV.
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(E) Comparison of the number of APs induced with increasing current injections from 
neurons treated with U18 (empty circles), after retigabine application (Rtg, black circles), 
and following washout (gray circles). Data from eight cells collected from three independent 
experiments. At 100 pA injected current, p < 0.0001 for U18 versus retigabine, p = 0.5 for 
U18 versus washout, and p < 0.0001 for retigabine versus washout.
(F) Comparison of the number of APs fired per unit of injected current fromNPC1I1061T 
mouse neurons before (empty circles) and after (black circles) retigabine application. Data 
from 14 cells collected from 3 independent experiments. At 100 pA, NPC1I1061T: 16 ± 2 
APs; NPC1I1061T + retigabine: 8 ± 3, p = 0.02.
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Figure 5. Plasma Membrane PtdIns(4,5)P2 Is Reduced in NPC1 Disease
(A) Schematic of the hypothesis: decreased IKCNQ2/3 density is due to reduced PM 
PtdIns(4,5)P2.
(B) Top: diagram illustrating PHPLCd1 as a PtdIns(4,5)P2 biosensor. Bottom: inverted 
confocal micrographs of healthy (left) and NPC1I1061T (right) patient fibroblasts transfected 
with PHPLCδ1. Insets show reduced intensity of PHPLCδ1 at the PM of NPC1I1061T patient 
fibroblasts.
(C) Comparison of the ratio of PHPLCδ1 fluorescence intensity at the PM to the cytoplasm 
(Cyt) in healthy (n = 21) and NPC1I1061T fibroblasts (n = 28, p = 0.0001).
(D) UPLC-MS/MS PtInsP2 measurements from healthy and NPC1I1061T patient fibroblasts 
(n = 5 independent cultures, p < 0.0001).
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(E) Mouse brain regions used for experiments: blue, cortex; orange, hippocampus; and 
green, cerebellum.
(F) Profile of the m/z ratio for the most abundant PtInsP2 isoform 38:4.
(G) Comparison of elution profiles of 38:4 PtInsP2 in WT and NPC1I1061T mice from each 
brain region (n = 3 mice).
(H) Comparison of the ratio of total PtInsP2 in NPC1I1061T to WT mice across brain regions. 
Total PtInsP2 includes all isoforms of PtInsP2 (e.g., 38:4, 36:2, 34:1).
(I) Summary of UPLC-MS/MS PtInsP2 measurements from WT and NPC1I1061T brains (n = 
3 animal, p = 0.03).
See also Figure S3.
Vivas et al. Page 27
Cell Rep. Author manuscript; available in PMC 2019 June 06.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 6. Exogenous Application of PtdIns(4,5)P2 Rescues Both IKCNQ2/3 and Excitability
(A) Schematic of the hypothesis: exogenous application of diC8-PtdIns(4,5)P2 rescues 
IKCNQ2/3 density and excitability.
(B) Comparison of IKCNQ2/3 recordings from neurons cultured overnight without U18 
(control) and patch without (black) or with (gray) 30 μM diC8-PtdIns(4,5)P2. Inset: protocol 
used to isolate IKCNQ2/3. Dotted line: 0 pA.
(C) Comparison of IKCNQ2/3 recordings from neurons cultured overnight with 1 μM U18 and 
patched without (red) or with (pink) 30 μM diC8-PtdIns(4,5)P2.
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(D) Summary of IKCNQ2/3 amplitude normalized to cell size from control (n = 8, empty), 
control patch with diC8-PtdIns(4,5)P (n = 8, gray), U18-treated neurons (n = 9, red), and 
U18-treated neurons patch with diC8-PtdIns(4,5)P2 (n = 11, pink).
(E) Top: schematic of current injection protocol. Center: family of voltage recordings shows 
a U18-treated neuron firing 9 APs with 40 pA current injection (black trace). Bottom: family 
of voltage recordings shows a U18-treated neuron patched with 30 μM diC8-PtdIns(4,5)P2 
in the recording pipette firing only 1 AP (bottom, black trace). U18-treated neuron patched 
with diC8-PtdIns(4,5)P2 does not fire any APs with less current injected (red trace). Dotted 
lines: −65 mV.
(F) Comparison of the number of APs induced with increasing current injections in U18-
treated neurons (red, n = 6) and U18-treated neurons patched with diC8-PtdIns(4,5)P2 (pink, 
n = 8).
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Figure 7. Upregulation of ABCA1 in NPC1 Disease Decreases PtdIns(4,5)P2 and Leads to 
Hyperexcitability
(A) Schematic of PtdIns(4,5)P2 synthesis. Relevant enzymes are in red.
(B) Blot stained for PtdIns(4,5)P2 metabolizing enzymes PIP5K1A, SYNJ1, and PLCβ1 
from cerebellums collected from NPC1I1061T and WT littermate mice.
(C) Summary of fold change of protein abundance in NPC1I1061T cerebellum relative to WT 
(n = 4 blots from different mice).
(D) Schematic of hypothesis: upregulation of ABCA1 reduces PtdIns(4,5)P2 levels.
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(E) Confocal micrographs of healthy (left) and NPC1I1061T (right) fibroblasts transfected 
with PHPLCδ1. Some healthy fibroblasts were treated with 1 μM T0901317, an LXR agonist, 
overnight (center). Insets show the reduced intensity of PHPLCδ1 at the PM from healthy 
fibroblasts treated with LXR agonist.
(F) Comparison of the ratio of PHPLCδ1 fluorescence intensity at the PM relative to the Cyt 
in healthy (empty, n = 13), healthy treated with LXR agonist (yellow, n = 15), and 
NPC1I1061T fibroblasts (red, n = 10).
(G) Inverted confocal micrographs of HeLa cells with endogenous levels of ABCA1 (WT, 
left) and overexpressed levels of ABCA1 (ABCA1, right) transfected with PHPLCδ1. Insets 
show the reduced intensity of PHPLCδ1 at the PM of HeLa cells with upregulated levels of 
ABCA1.
(H) Comparison of the ratio of PHPLCδ1 fluorescence intensity at the PM to the Cyt in WT 
(n = 40) and ABCA1 HeLa cells (n = 33).
(I) Top: blot stained for ABCA1 from cerebellum collected from NPC1I1061T and WT 
littermate mice. Bottom: summary of fold change of ABCA1 abundance in NPC1I1061T 
cerebellum relative to WT (n = 4 blots from different mice).
(J) Schematic of the hypothesis: inhibition of ABCA1 in NPC neurons rescues current 
density and excitability.
(K) Inset: protocol used to isolate KCNQ2/3 current. Comparison of KCNQ2/3 current 
recordings from neurons isolated from WT (black) and NPC1I1061T (red) mice. Some 
neurons isolated from NPC1I1061T were treated with 10 μM probucol (pink). Dotted line: 0 
pA. Bottom: summary of KCNQ2/3 current density from WT (n = 8, empty), NPC1I1061T (n 
= 6, red), and NPC1I1061T treated with probucol (n = 8, pink).
(L) Top: schematic of current injection protocol. Center: family of voltage recordings shows 
a probucol-treated NPC1I1061T neuron firing 2 APs with 40 pA current injection (black 
trace). Dotted line: −65 mV. Bottom: comparison of the number of APs induced with 
increasing current injections in probucol-treated NPC1I1061T neurons (pink, n = 9) and WT 
and NPC1I1061T neurons (same data as Figure 2).
See also Figures S4, S5, S6, and S7.
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KEY RESOURCES TABLE
REAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
Rabbit monoclonal anti-NPC1 ABCAM Cat # ab134113; RRID: AB_2734695
Rabbit polyclonal anti-KCNQ2 ABCAM Cat # ab22897; RRID: AB_775890
Mouse monoclonal anti-B-actin Thermo Scientific Cat # MA1–91399; RRID: 
AB_2273656
Goat anti-rabbit LI_COR biosciences Cat # P/N 926–68071; RRID: 
AB_10956389
Goat anti-mouse LI_COR biosciences Cat # P/N 925–32210; RRID: 
AB_2687825
Mouse anti-ABCA1 ABCAM Cat # Ab18180; RRID: AB_444302
Rabbit polyclonal anti-PIP5K1A Cell Signaling Technology Cat # 9693; RRID: AB_2164698
Rabbit polyclonal anti-SYNJ1 SIGMA Cat # HPA011916; RRID: 
AB_1857692
Rabbit monoclonal anti-PLC beta 1 ABCAM Cat # Ab182359
Chemicals, Peptides, and Recombinant Proteins
Rabbit polyclonal anti-ORPL2 Proteintech Cat # 14751–1-AP; RRID: 
AB_2156092
DiC8-PtdIns(4,5)P2 Avanti Polar Lipids Cat # 850185
PtdIns(4,5)P2 standard Avanti Polar Lipids Cat # LM-1904
U18666A SIGMA Cat # 662015
Retigabine APExBIO Cat # A3758
Probucol Fisher Cat # 15637105
LXR agonist, T0901317 SIGMA Cat # 575310
Experimental Models: Cell Lines
Human: Healthy Fibroblasts or wild type Fibroblasts: From a 
healthy male
Coriell Institute Cat # GM05659; RRID: CVCL_7434
Human: NPC1I1061T Fibroblasts: From a male patient with 
mutation in NPC1 (I1061T)
Coriell Institute Cat # GM18453; RRID: CVCL_DA78
Human: HeLa cells Provided by Dr. Alan Remaley 
(NHLBI)
N/A
Human: ABCA1-GFP HeLa cells Provided by Dr. Alan Remaley 
(NHLBI)
N/A
Experimental Models: Organisms/Strains
Mouse: (NPC1−/−): BALB/c strain knock-out of NPC1, 
NPCNIH, NPC1m1N
Provided by Dr. Daniel Ory 
(Washington University Saint Louis)
RRID: IMSR_JAX:003092
Mouse: NPC1I1061T: C57BL/6 Strain knock-in of 
NPC1I1061T
Provided by Dr. Daniel Ory. 
Praggastis et al., 2015
N/A
Mouse: wild type (WT): C57BL/6 Jackson Laboratory RRID: IMSR_JAX:000664
Oligonucleotides
NPC1I1061T allele 5′-tgatctgcacacttggaaccgag-3′ forward Praggastis et al., 2015 N/A
NPC1I1061T allele 5′-cactgccttgagcagcatctcag-3′ reverse Praggastis et al., 2015 N/A
siRNA targeting sequence: ABCA1 #1: 5′-
GCUCUUUCCUGAAUGUCAUCAACAA-3′
This paper N/A
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REAGENT or RESOURCE SOURCE IDENTIFIER
siRNA targeting sequence: ABCA1 #2: 5′-
CUACUACCUGACCUUGGUCAAGAAA-3′
This paper N/A
siRNA targeting sequence: ABCA1 #3: 5′-
CUUAUUUUUCUAGUCAGUAAACATT-3′
This paper N/A
Recombinant DNA
PHPLCδ1 plasmid Provided by Dr. Kees Jalink (the 
Netherlands Cancer Institute)
N/A
Software and Algorithms
ImageJ ImageJ RRID: SCR_003070
IGOR Pro WaveMetrics RRID: SCR_000325
Prism GraphPad RRID: SCR_002798
Microsoft Excel Microsoft RRID: SCR_016137
Masslynx Waters RRID: SCR_014271
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